Patient stratification will probably be a factor, we know one...

Patient stratification will probably be a factor, we know one patient in Cohort 3 SAD was at an early stage in disease progression, and we know all three patients in Cohort 4 were also stratified as early stage because it would provide the greatest opportunity to show an early efficacy signal. The diminishment of microperimetry vision happens at early stage, once beyond early stage it takes longer to discern improvements and/or lack of disease progression,

Shareholders are not privy to stratification data for Cohort 1 and Cohort 2 of SAD study, however with higher dose levels, as per MAD study, any data from them would most likely be valuable, probably more so if they were at an early stage of disease progression,

Having pointed this out, I am still very much excited by the continual positive unfoldment of PYC's RP11 program, I think what they are doing is first class!